跳至主導覽
跳至搜尋
跳過主要內容
臺北醫學大學 首頁
說明與常見問題
English
中文
首頁
專家檔案
研究單位
專案
研究成果
資料集
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
郭 俊男
助理教授
,
臨床藥學學科
藥師
,
臺北市立萬芳醫院
電子郵件
rencouter
tmu.edu
tw
h-index
215
引文
9
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2007
2025
每年研究成果
概覽
指紋
網路
專案
(4)
研究成果
(23)
類似的個人檔案
(6)
指紋
查看啟用 Chun-Nan Kuo 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Cohort Study
70%
Non Small Cell Lung Cancer
49%
Disease
38%
Adverse Event
32%
Survival Rate
32%
Colorectal Cancer
31%
Biological Marker
30%
Chemotherapy
30%
Immunotherapy
27%
Rivaroxaban
22%
Venous Thromboembolism
22%
Nephrolithiasis
22%
Pancreas Cancer
22%
Mucocutaneous Lymph Node Syndrome
22%
Non-Steroidal Anti-Inflammatory Drug
22%
Cancer Pain
22%
Medication Error
22%
Metastatic Breast Cancer
22%
Programmed Death 1 Receptor
22%
Case-Control Study
22%
Eribulin
22%
Hexachlorocyclohexane
22%
Gallstone
22%
Capecitabine
22%
Scabies
22%
Anaplastic Lymphoma Kinase Inhibitor
22%
Pembrolizumab
22%
Tipiracil
22%
Trifluridine
22%
Clinical Trial
20%
Combination Therapy
16%
Dermatitis
15%
Bleeding
12%
Overall Survival
12%
Sarcoptes Scabiei
11%
Muscle Cramp
11%
Pancytopenia
11%
Infection
11%
Disease Predisposition
11%
Paresthesia
11%
Hemodialysis
11%
Aplastic Anemia
11%
Anticarcinogen
11%
Breast Cancer
9%
Liver Cancer
9%
Lung Cancer
9%
Protein Tyrosine Kinase Inhibitor
9%
Anaplastic Lymphoma Kinase
8%
Cytotoxic T Lymphocyte Antigen 4
7%
Medicine and Dentistry
Malignant Neoplasm
47%
Cancer Immunotherapy
45%
Signal Transduction
45%
Health Care Cost
38%
Biological Marker
30%
Non Small Cell Lung Cancer
26%
Case-Control Study
22%
Nonsteroid Antiinflammatory Agent
22%
Kawasaki Disease
22%
Pervasive Developmental Disorder
22%
Biomedical Discipline
22%
Osteoporosis
22%
Programmed Death 1 Receptor
22%
Kidney Stone
22%
Cancer Pain Management
22%
4 Iodo 2,5 Dimethoxyamphetamine
22%
Colorectal Cancer
22%
Oncology
22%
Cohort Effect
22%
Disseminated Herpes Zoster
22%
Hexachlorocyclohexane
22%
Analgesia
22%
Epileptic Seizure
22%
ALK Inhibitor
22%
Pembrolizumab
22%
Cost-Effectiveness Analysis
22%
Programmed Death-Ligand 1
21%
Cohort Analysis
18%
Clinical Trial
18%
Quality Adjusted Life Year
16%
Combination Therapy
16%
Liver Cirrhosis
15%
Anticarcinogen
13%
Immunotherapy
13%
Breast Cancer
11%
Lung Cancer
11%
Liver Cancer
11%
Drug Therapy
11%
Hazard Ratio
10%
Scabies
9%
Survival Rate
8%
Proportional Hazards Model
8%
Anaplastic Lymphoma Kinase
8%
Adverse Event
7%
Cancer Therapy
7%
CTLA-4
7%
Radiation Therapy
7%
Opiate
7%
Acetylsalicylic Acid
6%
Neoplasm
6%
Nursing and Health Professions
Drug Therapy
51%
Survival Rate
25%
Pilot Study
22%
Elderly (Age Groups)
22%
Epidermal Growth Factor Receptor Kinase Inhibitor
22%
Nursing Home
22%
Medication Therapy Management
22%
Nephrolithiasis
22%
Disease
22%
Capecitabine
22%
Non Small Cell Lung Cancer
22%
Health Care Cost
22%
Metastatic Breast Cancer
22%
Eribulin
22%
Cohort Analysis
17%
Confidence Interval
14%
Ambulatory Care
11%
Independent Practice Association
11%
Malignant Neoplasm
11%
Overall Survival
9%
Medication Error
7%
Health Care Personnel
7%
